BRPI0413883A - composição e método para a administração de um composto farmacologicamente ativo a um mamìfero - Google Patents
composição e método para a administração de um composto farmacologicamente ativo a um mamìferoInfo
- Publication number
- BRPI0413883A BRPI0413883A BRPI0413883-0A BRPI0413883A BRPI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A BR PI0413883 A BRPI0413883 A BR PI0413883A
- Authority
- BR
- Brazil
- Prior art keywords
- active compound
- pharmacologically active
- compositions
- present
- mammal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 5
- 241000124008 Mammalia Species 0.000 title abstract 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 abstract 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 abstract 1
- 239000004100 Oxytetracycline Substances 0.000 abstract 1
- -1 compound salt Chemical class 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 229960002464 fluoxetine Drugs 0.000 abstract 1
- 239000007972 injectable composition Substances 0.000 abstract 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 abstract 1
- 229960000625 oxytetracycline Drugs 0.000 abstract 1
- 235000019366 oxytetracycline Nutrition 0.000 abstract 1
- 229960005224 roxithromycin Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 abstract 1
- 229960002722 terbinafine Drugs 0.000 abstract 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 abstract 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 abstract 1
- 229960000223 tilmicosin Drugs 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/650,262 US20050049210A1 (en) | 2003-08-27 | 2003-08-27 | Methods for the controlled delivery of pharmacologically active compounds |
| PCT/US2004/011823 WO2005025488A2 (en) | 2003-08-27 | 2004-04-16 | Methods for the controlled delivery of pharmacologically active compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413883A true BRPI0413883A (pt) | 2006-10-24 |
Family
ID=34217115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413883-0A BRPI0413883A (pt) | 2003-08-27 | 2004-04-16 | composição e método para a administração de um composto farmacologicamente ativo a um mamìfero |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050049210A1 (enExample) |
| EP (1) | EP1667654A2 (enExample) |
| JP (1) | JP2007503433A (enExample) |
| AU (1) | AU2004271909A1 (enExample) |
| BR (1) | BRPI0413883A (enExample) |
| CA (1) | CA2535373A1 (enExample) |
| WO (1) | WO2005025488A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887487B2 (en) * | 2001-10-19 | 2005-05-03 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
| US20070196398A1 (en) * | 2006-02-17 | 2007-08-23 | Murthy Yerramilli V S | Fluoroquinolone fatty acid salt compositions |
| CN101983632A (zh) * | 2010-10-11 | 2011-03-09 | 西北农林科技大学 | 一种复方替米考星纳米乳抗菌药物及其制备方法 |
| US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
| JP6396333B2 (ja) | 2013-02-12 | 2018-09-26 | ベンド・リサーチ・インコーポレーテッドＢｅｎｄ Ｒｅｓｅａｒｃｈ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 低水溶性活性物質の固体分散体 |
| US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
| CN103463480A (zh) * | 2013-08-22 | 2013-12-25 | 邢波 | 一种治疗经络阻塞型急性颈部淋巴结炎的中药制备方法 |
| CN107873024A (zh) * | 2015-02-09 | 2018-04-03 | 塞尔利克斯生物私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
| CN107184553A (zh) * | 2017-06-14 | 2017-09-22 | 天津佰力喜动物药业有限公司 | 一种替米考星脂质体分散剂的制备方法 |
| CN108392467A (zh) * | 2018-05-30 | 2018-08-14 | 山东德信生物科技有限公司 | 一种替米考星注射液及其制备方法 |
| CN109077999A (zh) * | 2018-08-31 | 2018-12-25 | 田红卫 | 一种长效缓释替米考星注射液及其制备方法 |
| CN109655534B (zh) * | 2018-11-08 | 2021-11-30 | 佛山市正典生物技术有限公司 | 一种替米考星颗粒含量的检测方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US28875A (en) * | 1860-06-26 | Improvement in desulphurizing ores and coal | ||
| ES488154A0 (es) * | 1979-02-05 | 1981-04-16 | Schering Corp | Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol |
| US4235892A (en) * | 1979-02-05 | 1980-11-25 | Schering Corporation, Patent Dept. | 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor |
| US4361557A (en) * | 1980-01-28 | 1982-11-30 | Schering Corporation | 1-Aryl-2-acylamido-3-fluoro-1-propanol acylates, methods for their use as anti-bacterial agents and compositions useful therefor |
| JPS5746986A (en) * | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
| US4876352A (en) * | 1988-09-14 | 1989-10-24 | Schering Corporation | Pressurized fluorination of hydroxy alkyl groups |
| US5574020A (en) * | 1989-09-28 | 1996-11-12 | Eli Lilly And Company | Tilmicosin formulation |
| US5082863A (en) * | 1990-08-29 | 1992-01-21 | Schering Corporation | Pharmaceutical composition of florfenicol |
| NZ250394A (en) * | 1990-10-25 | 1994-10-26 | Schering Corp | Fluorinated and hydroxylated oxazoline compounds |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5352832A (en) * | 1992-12-18 | 1994-10-04 | Schering Corporation | Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates |
| WO1995013824A1 (en) * | 1993-11-15 | 1995-05-26 | Celtrix Pharmaceuticals, Inc. | Method of treating renal disease by administering igf-i and igfbp-3 |
| US6110905A (en) * | 1994-07-09 | 2000-08-29 | Norbrook Laboratories Limited | Long-acting oxytetracycline composition |
| US6333021B1 (en) * | 1994-11-22 | 2001-12-25 | Bracco Research S.A. | Microcapsules, method of making and their use |
| US6310053B1 (en) * | 1995-07-05 | 2001-10-30 | Norbrook Laboratories Limited | Long-acting oxytetracycline composition |
| US5958888A (en) * | 1996-07-02 | 1999-09-28 | Merial, Inc. | Water miscible macrolide solutions |
| US5723447A (en) * | 1996-07-02 | 1998-03-03 | Rhone Merieux, Inc. | Water miscible erythromycin solutions |
| US5663361A (en) * | 1996-08-19 | 1997-09-02 | Schering Corporation | Process for preparing intermediates to florfenicol |
| UA51730C2 (uk) * | 1996-09-04 | 2002-12-16 | Ебботт Лабораторіз | 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців |
| US5766506A (en) * | 1996-09-12 | 1998-06-16 | The Dow Chemical Company | Hard water compatible phosphate-containing heat transfer fluids |
| SE511313C2 (sv) * | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
| US6239112B1 (en) * | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
| US5977133A (en) * | 1998-08-19 | 1999-11-02 | Abbott Laboratories | Pyridone antibiotic with improved safety profile |
| US6174540B1 (en) * | 1998-09-14 | 2001-01-16 | Merck & Co., Inc. | Long acting injectable formulations containing hydrogenated caster oil |
| US6140374A (en) * | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| US6887487B2 (en) * | 2001-10-19 | 2005-05-03 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
| AU2002364212B2 (en) * | 2001-12-21 | 2007-09-20 | Shire Laboratories Inc. | Oral capsule formulation with increased physical stability |
-
2003
- 2003-08-27 US US10/650,262 patent/US20050049210A1/en not_active Abandoned
-
2004
- 2004-04-16 AU AU2004271909A patent/AU2004271909A1/en not_active Abandoned
- 2004-04-16 EP EP04816168A patent/EP1667654A2/en not_active Withdrawn
- 2004-04-16 WO PCT/US2004/011823 patent/WO2005025488A2/en not_active Ceased
- 2004-04-16 CA CA002535373A patent/CA2535373A1/en not_active Abandoned
- 2004-04-16 BR BRPI0413883-0A patent/BRPI0413883A/pt not_active IP Right Cessation
- 2004-04-16 JP JP2006524614A patent/JP2007503433A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004271909A1 (en) | 2005-03-24 |
| WO2005025488A3 (en) | 2005-05-12 |
| EP1667654A2 (en) | 2006-06-14 |
| JP2007503433A (ja) | 2007-02-22 |
| US20050049210A1 (en) | 2005-03-03 |
| CA2535373A1 (en) | 2005-03-24 |
| WO2005025488A2 (en) | 2005-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0213425A (pt) | Composições injetáveis para a liberação controlada de composto farmacologicamente ativo | |
| US6368618B1 (en) | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs | |
| BRPI0413883A (pt) | composição e método para a administração de um composto farmacologicamente ativo a um mamìfero | |
| Rosenblum et al. | Studies in cardiac necrosis: I. Production of cardiac lesions with sympathomimetic amines | |
| KR20050047525A (ko) | 담체 | |
| BRPI0822162B8 (pt) | composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal | |
| BR0307540A (pt) | Preparação farmacêutica em forma de filme ou em forma de lâmina para administrar substâncias ativas, uso da preparação farmacêutica e processo para a administração oral de substância(s) farmaceuticamente ativa(s) dotadas de sabor amargo | |
| PT660707E (pt) | Amantadina e compostos relacionados para utilizacao no tratamento da neuropatia periferica | |
| AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
| SA93140384B1 (ar) | كربامات الفينيل | |
| BRPI0711482B8 (pt) | combinação farmacêutica que compreende 3-(3-dimetilamino-1 etil-2-metil-propil) fenol e uma nsaid | |
| AR032730A1 (es) | Desnaturalizantes para las sales aminas simpaticomimeticas | |
| CO6190598A2 (es) | Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| NO20085414L (no) | Farmasoytiske preparater for vedvarende frigivelse av fenylefrin | |
| BR112013020456B1 (pt) | nova composição antifúngica | |
| RS53804A (sr) | Parenteralna kompozicija paracetamola | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| WO2004091541A3 (en) | Methods for the controlled delivery of pharmacologically active compounds | |
| BR0111051A (pt) | Produto farmacêutico e dose farmacêutica diária para administração a um paciente, regime de dose prover um efeito anti-androgênico e um efeito anti-estrogênico em um paciente, uso de um composto e de tamoxifeno ou de um sal ou solvato farmaceuticamente aceitável destes, e, método para prover um efeito anti-androgênico em um paciente | |
| CO6400019A1 (es) | Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion | |
| BR0013582A (pt) | Agonistas retinóides seletivos para rar | |
| Baldessarini et al. | Inhibition of catechol-O-methyl transferase by catechols and polyphenols | |
| Riegert et al. | Effects of ethanol and 3, 4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain | |
| Ye et al. | Anesthetic effects on autophagy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |